Brief: Invivyd Doses First Participants In Phase 1 Trial Of VYD222, A Novel Monoclonal Antibody Candidate For Covid-19
30/03/2023 21:08
March 30 (Reuters) - Invivyd Inc IVVD.O :
* INVIVYD DOSES FIRST PARTICIPANTS IN PHASE 1 TRIAL OF
VYD222, A
NOVEL MONOCLONAL ANTIBODY CANDIDATE FOR COVID-19
* INVIVYD INC - EXPECTS PRELIMINARY DATA READOUTS FROM PHASE
1
TRIAL IN Q2
* INVIVYD INC - ANTICIPATES ADDITIONAL CLINICAL READOUTS
FROM
VYD222 PROGRAM THROUGHOUT REMAINDER OF 2023
Source text for Eikon: ID:nGNX268K1C
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview